Tag: ASX:CIM

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter-trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter-trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

Update 21/10: CIMIC Group today announced its financial result for the nine months to 30 September 2021:
 NPAT of $303m for 9m of 2021
 Group revenue growth of 9.2%2 YoY to $10.9bn, revenue increase of 6.8% YoY to$7.1bn
 Revenue growth achieved in Australian Construction and Services
 EBITDA, PBT and NPAT margins resilient at 9.6%, 5.1% and 4.3% respectively, despite 3Q21 COVID-19 impact

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

.

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

.

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

.

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

Buy Dec $20 call options as a stock replacement strategy. For more detail, please call 1300 614 002.

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

Buy Dec $20 call options as a stock replacement strategy. For more detail, please call 1300 614 002.

Cimic Group 1H21 earnings beat market expectations, with group revenue growth of 10.6%2 to $7.1bn and NPAT of $208m for HY21.

Factoring balance further reduced by $243m YTD from $976m at December 2020 to $733m at June 2021. 10.4bn of new work awarded in HY21, with total work in hand increasing to $33.3bn.

FY21 NPAT guidance of $400m-$430m maintained, subject to market conditions.

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high-risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

Buy Dec $20 call options as a stock replacement strategy. For more detail, please call 1300 614 002.